A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
NCT07255209 on ClinicalTrials.gov · last registry update 2026-01-08
A small phase 3 — 180 participants, against a typical 424. Due to report 31 October 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in BMI. Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Drug
- mazdutide
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Enrollment
- 180
- Started
- 2025-12-29
- Primary completion
- 2027-10-31 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Change from Baseline in BMI
Conditions studied
Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.